Searched for
PSORIASIS MANAGEMENT
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- No facials, no expensive beauty ingredients: Actress Priyanka Chopra Jonas reveals her beauty secret of her grandmother who passed away 94 with 'barely any wrinkles’Priyanka Chopra revealed her grandmother's secret to youthful skin: coconut oil. This natural ingredient combats microbes and reduces infla...
- 31-year-old suffered from rare immune condition, could barely do his job, shares the one habit which helped him healA 31-year-old man's psoriasis severely worsened after COVID-19, leading to significant weight loss and emotional distress. He found relief ...
- Sun Pharma launches Ilumya for psoriasis treatment in IndiaSun Pharmaceutical Industries has launched its innovative drug Ilumya in India. This medication treats moderate-to-severe plaque psoriasis....
- Sun Pharma brings global psoriasis drug ILUMYA to Indian marketSun Pharmaceutical Industries has launched its innovative biologic drug, ILUMYA, in India for moderate-to-severe plaque psoriasis. This nov...
- Does dandruff lead to hair fall or baldness? AIIMS-trained skin doctor explains what is fact and what is mythDandruff causes temporary hair fall due to scalp inflammation, not permanent root damage, according to Dr. Gaurang Krishna. Genetic factors...
- Psoriatic Arthritis explained: Early signs, causes, and how to stop joint damage before it startsPsoriatic arthritis affects skin and joints with inflammation. This autoimmune condition causes pain, stiffness, and swelling. Early detect...
- Eli Lilly forays into dermatological space with launch of psoriasis drugEli Lilly has launched a new drug to treat moderate-to-severe plaque psoriasis in India. The drug, Copellor, is designed to specifically ta...
- Health ministry decides against including Itolizumab in clinical management protocols for COVID-19The permission to market the drug was granted for the treatment of cytokine release syndrome in 'moderate' to 'severe' Acute Respiratory Di...
- Sun Pharma, Hikma ink exclusive pact for plaque psoriasis drug for MENA regionUnder the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA...
- Does winter mean psoriasis for you? Avoid stress, choose fragrance-free productsOne of the most common skin conditions, psoriasis causes skin cells to build up, and form shiny scales and itchy, dry red patches.
- Sun Pharma signs licening pact with spanish firm Almirall for psoriasis drugIn return, the Indian company will receive an initial upfront payment of $50 million and be eligible for development and regulatory milesto...
- Nine new drugs under clinical stage: Dr Reddy'sAccording to a filing with US SEC, the drug maker said as of March 31, 2014, it had 20 active products in the proprietary products pipeline.
- Biocon rolls out its first biologic drug for the treatment of psoriasisCalled ALZUMAb, it took 10 years in the making and "is recognition of innovation done by research and development wing of Biocon," said Kir...
- Biocon seeking partners to develop, market psoriasis drugBiotechnology major Biocon today said it is looking for partners to develop and market its novel biologic drug Itolizumab
- Biocon to launch psoriasis drug novel biologic in JulyThe company had received marketing authorisation for Itolizumab from the Drugs Controller General of India (DCGI) in January, 2013.
- Biocon eyes Rs 100 cr from psoriasis drug in next four yearsThe product would be manufactured and formulated as an infusion drug at Biocon's biopharma manufacturing facility at Biocon Park, Bangalore.
Load More
